Brokerages Set Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target at $52.56

Shares of Keros Therapeutics, Inc. (NASDAQ:KROS) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat reports. Six analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $52.56.

Several research firms have recently commented on KROS. Guggenheim restated a “neutral” rating on shares of Keros Therapeutics in a research report on Friday, January 17th. HC Wainwright decreased their target price on shares of Keros Therapeutics from $100.00 to $47.00 and set a “buy” rating for the company in a research report on Friday, December 13th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research note on Tuesday, November 5th. They issued a “buy” rating on the stock. Cantor Fitzgerald downgraded Keros Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 21st. Finally, William Blair cut Keros Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Thursday, December 12th.

Keros Therapeutics Price Performance

NASDAQ:KROS opened at $10.49 on Thursday. Keros Therapeutics has a 12-month low of $9.77 and a 12-month high of $73.00. The business has a 50 day simple moving average of $22.31 and a 200 day simple moving average of $43.44. The firm has a market capitalization of $424.95 million, a P/E ratio of -2.01 and a beta of 1.39.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. FMR LLC raised its holdings in shares of Keros Therapeutics by 3.8% in the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company’s stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC increased its holdings in shares of Keros Therapeutics by 18.7% in the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company’s stock valued at $110,194,000 after buying an additional 298,694 shares in the last quarter. Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% during the 3rd quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company’s stock valued at $55,025,000 after acquiring an additional 577,220 shares during the last quarter. Holocene Advisors LP boosted its stake in shares of Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company’s stock worth $48,959,000 after acquiring an additional 154,784 shares in the last quarter. Finally, Geode Capital Management LLC grew its holdings in shares of Keros Therapeutics by 6.8% in the 3rd quarter. Geode Capital Management LLC now owns 725,621 shares of the company’s stock worth $42,146,000 after acquiring an additional 46,041 shares during the last quarter. 71.56% of the stock is owned by institutional investors and hedge funds.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.